P-1584

Ian Morrissey*1, Prabhavathi Fernandes2, Barbara Lemos1, Stephen P. Hawser1 ¹IHMA Europe, Sárl, Epalinges, Switzerland. ² Cempra, Inc., Chapel Hill, USA *Corresponding author

9A Route de la Corniche, Epalinges 1066, Switzerland Email: imorrissey@ihmainc.com Tel: +44 (0)1279 724929

IHMA Europe, Sárl

Revised Abstract

Background: Solithromycin is a fourth-generation macrolide, the first fluoroketolide that is under development in oral and intravenous formulations in Phase 3 clinical trials for the treatment of moderate to moderately-severe community-acquired bacterial pneumonia. This study evaluated the in vitro activity of solithromycin against respiratory streptococcal isolates collected in Europe, Asia-Pacific and North America during 2012-2013.

Methods: A total of 1,070 streptococci, 927 S. pneumoniae and 143 S. pyogenes, were collected from Europe, Asia-Pacific and North America. Isolates were tested in a central laboratory with MIC and susceptibility for solithromycin and comparators determined according to CLSI broth microdilution breakpoints³. Provisional methodology and susceptible, intermediate and resistant breakpoints of 1, 2 and 4 mg/L were used for solithromycin against S. pneumoniae.

Results: MIC_{90} (mg/L) and percent susceptible (%S) data are shown in the Table:

C nnovembries		501	A/C	AZT	СТХ	CLI	ERY	LVX	мох	PEN	TEL	VAN
S. pneumoniae		SOL	A/C	AZI	CIX	CLI	EKI	LVX	IVIOX	PEN	IEL	VAIN
Europe (n=418)	MIC_{90}	0.06	2	> 1	1	> 0.5	> 0.5	2	0.25	2	0.12	0.5
	%S	100	90	71	92	77	72	97	98	63	100	100
Asia-Pacific (129)	MIC ₉₀	0.5	4	>1	2	>0.5	>0.5	2	0.25	4	0.5	0.5
	%S	100	85	29	77	42	29	98	99	51	99	100
North America (380)	MIC ₉₀	0.25	2	>1	1	>0.5	>0.5	1	0.25	2	0.5	0.5
	%S	100	90	56	91	80	57	100	100	59	99	100
S. pyogenes		SOL	A/C	AZT	СТХ	CLI	ERY	LVX	мох	PEN	TEL	VAN
Europe (83)	MIC ₉₀	0.03	0.03	1	0.03	0.06	0.25	2	0.25	≤0.06	0.06	0.5
	%S	NB	NB	89	100	96	90	100	NB	100	NB	100
Asia-Pacific (24)	MIC ₉₀	0.5	0.03	>1	0.03	>0.5	>0.5	2	0.25	≤0.06	>2	0.5
	%S	NB	NB	33	100	54	33	96	NB	100	NB	100
North America (36)	MIC ₉₀	0.06	0.03	>1	0.03	0.12	>0.5	2	0.5	≤0.06	0.03	0.5
	%S	NB	NB	83	100	97	81	97	NB	97	NB	100

A/C, amoxicillin/clavulanic acid; AZT, azithromycin; CTX, ceftriaxone; CLI, clindamycin; ERY, erythromycin; LVX, levofloxacin; MOX, moxifloxacin; PEN, penicillin; SOL, solithromycin; TEL, telithromycin; VAN, vancomycin; NB, no breakpoints available

Conclusions: Solithromycin showed very good activity against isolates from the different regions with MIC_{90} ranging from 0.06-0.5 mg/L to 0.03-0.5 mg/L, for pneumococci and S. pyogenes, respectively. These data positively support the continued development of solithromycin for the treatment of respiratory infections caused by streptococci.

Introduction

Solithromycin is a fluoroketolide available in both oral and intravenous formulations. It is being developed for the treatment of community-acquired bacterial pneumonia (CABP) and urethritis. Solithromycin is currently undergoing Phase 3 clinical trials for the treatment of moderate to moderately-severe CABP. Phase 2 clinical trial data showed solithromycin to be equivalent to levofloxacin in efficacy and to have a more favourable safety profile [1].

This study evaluated the *in vitro* activity of solithromycin against more than 1000 respiratory streptococcal isolates collected in Europe, Asia-Pacific and North America during 2012-2013.

Materials & Methods

- A total of 927 S. pneumoniae and 143 S. pyogenes were tested from Europe, Asia-pacific and North America (Table 1). Isolates were identified to the species level and MICs determined at a central testing laboratory (IHMA Europe, located in Epalinges, Switzerland).
- Minimum inhibitory concentrations (MICs) determined by the Clinical and Laboratory Standards Institute (CLSI) recommended broth microdilution testing method using panels prepared at IHMA [2].
- MIC interpretive criteria mainly followed published guidelines of CLSI published in 2013 [3], but for tigecycline FDA breakpoints were used [4]. Provisional breakpoints of 1, 2 and 4 mg/L were used for solithromycin against S. pneumoniae.
- Quality controls were performed on each day of testing using appropriate ATCC control strains, following CLSI and manufacturer guidelines. Results were included in the analysis only when corresponding QC results were within the acceptable ranges [3].

References

- Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson BD, Fernandes P. 2013. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 57:2526-34
- 2. Clinical Laboratory Standards Institute. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards – Ninth Edition. CLSI document M07-A9. Wayne, PA.
- 3. Clinical and Laboratory Standards Institute. 2013. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement. CLSI Document M100-S23. Wayne, PA.
- 4. Tygacil®, 2010. Tigecycline FDA prescribing information. Pfizer, Inc., Collegeville,

Acknowledgements

This study was sponsored by a grant from Cempra Pharmaceuticals.

Results

Summary of MIC and susceptibility data for solithromycin and comparators against S. pneumoniae and S. pyogenes isolated from Europe, North America and Asia-Pacific are given in Tables 2 and 3. The cumulative percentage MIC distributions for solithromycin are compared for each species by world region in Figures 1 and 2.

 Table 1: Number of isolates investigated and region of origin.

Region	Streptococcus pneumoniae	Streptococcus pyogenes
Europe	418	83
North-America	380	36
Asia-Pacific	129	24
TOTAL	927	143

Figure 1: Cumulative percentage MIC distribution for solithromycin and azithromycin against S. pneumoniae from different regions of the world.




Figure 2: Cumulative percentage MIC distribution for solithromycin and azithromycin against S. pyogenes from different regions of the world.




Table 2: Summary MIC and susceptibility data for solithromycin and comparators against 927 S.

Antimicrobial		Percentage:			MIC (mg/L):				An
agents	Region	Susceptible	Intermediate	Resistant	50%	90%	MIN	MAX	ag
	Europe (418)	100	0.0	0.0	0.008	0.06	≤ 0.001	0.5	
Solithromycin ^a	North America (380)	100	0.0	0.0	0.008	0.25	0.002	0.5	Sc
·	Asia-Pacific (129)	100	0.0	0.0	0.06	0.5	0.004	1 0.5 0.5 1 0.5 5 > 4 5 > 4 5 > 4 8 > 1 8 > 1 8 > 1 5 > 2 5 > 2 5 > 2 5 > 0.5 6 > 0.5 6 > 0.5 6 > 0.5 6 > 0.5 6 > 4 7 > 7 > 7	
	Europe (418)	90.2	6.5	3.4	0.03	2	≤ 0.015	> 4	
Amoxicillin Clavulanic Acid	North America (380)	90.3	3.4	6.3	0.03	2	≤ 0.015	> 4	Aı
	Asia-Pacific (129)	84.5	7.0	8.5	0.06	4	≤ 0.015	0.5 1 >4 >4 >4 >4 >1 >1 >1 >1 >1 >2 >2 >2 >0.5 >0.5 >0.5 >0.5 >0.5 >0.5 >0.5 >4 >4 >4 >2 >2 >2 >2 >4 >4 >4 >4 >2 >2 >2 >2 >2 >2 >2 >2 >2 >2 >2 >2 >2	CI
	Europe (418)	71.3	0.7	28.0	0.12	> 1	≤ 0.03	> 1	
Azithromycin	North America (380)	56.3	1.1	42.6	0.12	> 1	≤ 0.03	> 1	Az
,	Asia-Pacific (129)	28.7	0.8	70.5	> 1	> 1	≤ 0.03	> 1	
Ceftriaxone	Europe (418)	91.6	6.5	1.9	0.03	1	≤ 0.015	> 2	
	North America (380)	91.3	7.9	0.8	0.03	1	≤ 0.015	> 2	Ce
	Asia-Pacific (129)	76.7	17.8	5.4	0.12	2	≤ 0.015	> 2	
	Europe (418)	77.0	0.5	22.5	0.03	> 0.5	≤ 0.015	> 0.5	
Clindamycin	North America (380)	79.7	0.3	20.0	0.06	> 0.5	≤ 0.015	> 0.5	CI
	Asia-Pacific (129)	41.9	0.8	57.4	> 0.5	> 0.5	≤ 0.015	> 0.5	
	Europe (418)	72.3	0.5	27.3	≤ 0.06	> 0.5	≤ 0.06	> 0.5	En
Erythromycin	North America (380)	56.8	0.0	43.2	≤ 0.06	> 0.5	≤ 0.06	> 0.5	
	Asia-Pacific (129)	29.5	0.0	70.5	> 0.5	> 0.5	≤ 0.06	> 0.5	
	Europe (418)	97.4	0.7	1.9	1	2	≤ 0.25	> 4	Le
Levofloxacin	North America (380)	99.7	0.0	0.3	1	1	0.5	> 4	
	Asia-Pacific (129)	98.5	0.0	1.6	1	2	0.5	> 4	
Moxifloxacin	Europe (418)	98.3	0.5	1.2	0.12	0.25	≤ 0.03	> 2	М
	North America (380)	99.7	0.0	0.3	0.12	0.25	0.06	> 2	
	Asia-Pacific (129)	99.2	0.0	0.8	0.12	0.25	0.06	> 2	
	Europe (418)	63.4	20.6	16.0	≤ 0.06	2	≤ 0.06	> 4	
Penicillin	North America (380)	59.5	28.7	11.8	≤ 0.06	2	≤ 0.06	> 4	Pe
	Asia-Pacific (129)	51.2	20.2	28.7	≤ 0.06	4	≤ 0.06	> 4	
	Europe (418)	100	0.0	0.0	0.008	0.12	≤ 0.002	1	
Telithromycin	North America (380)	99.5	0.5	0.0	0.015	0.5	0.004	2	Te
•	Asia-Pacific (129)	99.2	0.8	0.0	0.06	0.5	0.008	2	
	Europe (418)	95.2	0.0	4.8	0.03	0.06	0.015	0.25	
Tigecycline	North America (380)	75.8	0.0	24.2	0.06	0.12	0.015	> 0.5	Ti
rigecycline	Asia-Pacific (129)	72.1	0.0	27.9	0.06	0.12	0.015	0.5	
	Europe (418)	100	0.0	0.0	0.25	0.5	0.12	1	
Vancomycin	North America (380)	100	0.0	0.0	0.25	0.5	0.06	0.5	Va
·	Asia-Pacific (129)	100	0.0	0.0	0.25	0.5	0.12	0.5	

^aProvisional breakpoints of ≤1 (S), 2 (I) and 4 (R) mg/L were used for solithromycin

Table 3. Summary MIC and susceptibility data for solithromycin and comparators against 143 S. pyogenes.

Antimicrobial	Danie u		MIC (mg/L)					
agents	Region	Susceptible	Intermediate	Resistant	50%	90%	MIN	MAX
Solithromycin ^a	Europe (83)	100	0.0	0.0	0.015	0.03	0.008	0.5
	North America (36)	100	0.0	0.0	0.015	0.06	0.008	0.25
	Asia-Pacific (24)	100	0.0	0.0	0.06	0.5	0.008	1
A	Europe (83)	NA	NA	NA	≤ 0.015	0.03	≤ 0.015	0.12
Amoxicillin	North America (36)	NA	NA	NA	≤ 0.015	0.03	≤ 0.015	0.03
Clavulanic Acid	Asia-Pacific (24)	NA	NA	NA	≤ 0.015	0.03	≤ 0.015	0.03
	Europe (83)	89.2	2.4	8.4	0.12	1	0.06	> 1
Azithromycin	North America (36)	83.3	0.0	16.7	0.12	> 1	0.12	> 1
	Asia-Pacific (24)	33.3	0.0	66.7	> 1	> 1	0.12	> 1
	Europe (83)	100	-	-	0.03	0.03	≤ 0.015	0.5
Ceftriaxone	North America (36)	100	-	-	0.03	0.03	≤ 0.015	0.03
	Asia-Pacific (24)	100	-	-	0.03	0.03	≤ 0.015	0.03
	Europe (83)	96.4	0.0	3.6	0.06	0.06	0.03	> 0.5
Clindamycin	North America (36)	97.2	2.8	0.0	0.06	0.12	0.03	0.5
	Asia-Pacific (24)	54.2	0.0	45.8	0.12	> 0.5	0.06	> 0.5
	Europe (83)	90.4	0.0	9.6	≤ 0.06	0.25	≤ 0.06	> 0.5
Erythromycin	North America (36)	80.6	0.0	19.4	≤ 0.06	> 0.5	≤ 0.06	> 0.5
	Asia-Pacific (24)	33.3	0.0	66.7	> 0.5	> 0.5	≤ 0.06	> 0.5
	Europe (83)	100	0.0	0.0	1	2	0.5	2
Levofloxacin	North America (36)	97.2	0.0	2.8	0.5	2	0.5	> 4
	Asia-Pacific (24)	95.8	0.0	4.2	1	2	≤ 0.25	> 4
Moxifloxacin	Europe (83)	NA	NA	NA	0.12	0.25	0.06	1
	North America (36)	NA	NA	NA	0.12	0.5	0.06	2
	Asia-Pacific (24)	NA	NA	NA	0.25	0.25	0.06	> 2
	Europe (83)	98.8	-	-	≤ 0.06	≤ 0.06	≤ 0.015 0.06 0.12 ≤ 0.015 ≤ 0.015 ≤ 0.015 0.03 0.06 ≤ 0.06 ≤ 0.06 0.5 0.5 0.05 0.06 0.015 0.015 0.015 0.015 0.03 0.03	≤ 0.00
Penicillin	North America (36)	97.2	-	-	≤ 0.06	≤ 0.06	≤ 0.06	0.25
	Asia-Pacific (24)	100	-	-	≤ 0.06	≤ 0.06	≤ 0.06	0.12
Telithromycin	Europe (83)	NA	NA	NA	0.015	0.06	0.015	> 2
	North America (36)	NA	NA	NA	0.015	0.03	0.015	0.5
	Asia-Pacific (24)	NA	NA	NA	0.12	> 2	0.015	> 2
Tigecycline	Europe (83)	100	-	-	0.06	0.06	0.03	0.12
	North America (36)	100	-	-	0.06	0.06	0.015	0.06
	Asia-Pacific (24)	100	-	-	0.06	0.12	0.03	0.25
Vancomycin	Europe (83)	100	-	-	0.25	0.5	0.25	0.5
	North America (36)	100	-	-	0.5	0.5	0.25	1
	Asia-Pacific (24)	100	-	-	0.25	0.5	0.25	0.5

Conclusions

- Solithromycin showed very good activity against S. pneumoniae and S. pyogenes with $MIC_{90} \le 0.5$ mg/L for all the regions of the world included in this study, Europe, North-America and Asia-Pacific.
- For both species, MIC_{90} Europe $< MIC_{90}$ North America $< MIC_{90}$ Asia-Pacific.
- Solithromycin was considerably more active than macrolides and penicillins against S. pneumoniae and more active than macrolides against S. pyogenes.
- Solithromycin was also more active than telithromycin.
- These data show that solithromycin could be a good alternative to treat respiratory infections caused by S. pneumoniae and S. pyogenes especially in regions of the world like Asia where there is a very high level of resistance to macrolides and penicillins and thus strongly support the continued development of this antibiotic.